Non-randomized, Open-label, Multi-center Phase II Study of GW786034 to Evaluate the Administration of Oral GW786034 in Subjects With Ovarian Cancer

Trial ID #	NCT00281632
Phase	II
Drug Class	Angiogenesis Inhibitors: Multi-targeted RTK
Drug Name	Pazopanib
Alternate Drug Names	Votrient
Drugs in Trial	Pazopanib
Eligible Participant	Recurrent ovarian cancer (after CR to first-line platinum-based therapy)
Patients Enrolled	36; 27 Pt-S, 6 Pt-R, 3 Pt-Rf
Therapy Setting	Recurrence
Study Design	Non-randomized
Endpoints	ORR, evaluated per RECIST or CA125
Efficacy	ORR: 17.6% (3PR, n=17, RECIST) ORR: 31% (CA125)
Clinically Significant Adverse Events	Serious AE: none Grade 3-4 AE: elevated liver enzymes (8%) and edema (1 patient)
Conclusion	Promising activity of single agent pazopanib
Reference	Friedlander M et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol (2010) 119(1):32 -7 https://www.ncbi.nlm.nih.gov/pubmed/20584542